{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:52:40Z","timestamp":1791460360161,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.yrtph.2026.106240","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:04:50Z","timestamp":1788969890000},"page":"106240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Determining the value of subchronic or chronic animal toxicity testing in identifying new target organ findings"],"prefix":"10.1016","volume":"172","author":[{"given":"Paul","family":"Baldrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106240_bib1","article-title":"What have we learned from chronic toxicity studies in non-human-primates with monoclonal antibodies? What are the 3Rs opportunities?","author":"Allais","year":"2024","journal-title":"Toxicologist: Late-Breaking Supplement (Poster at Society of Toxicology 63rd annual meeting"},{"issue":"4","key":"10.1016\/j.yrtph.2026.106240_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101628","article-title":"Nonclinical toxicity study duration in AAV gene therapy development: evidence from industry survey supports adequacy of short-term assessments","volume":"33","author":"Assaf","year":"2025","journal-title":"Mol. Ther. Meth. Clin. Dev."},{"issue":"10","key":"10.1016\/j.yrtph.2026.106240_bib3","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s41416-020-01033-x","article-title":"Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials","volume":"123","author":"Atkins","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yrtph.2026.106240_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2025.105809","article-title":"Current nonclinical testing paradigm to allow clinical entry for pharmaceutical drug candidates","volume":"159","author":"Baldrick","year":"2025","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106240_bib6","article-title":"Oncology drugs: target organ findings seen in animal toxicity testing","volume":"68","author":"Baldrick","year":"2026","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106240_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.104869","article-title":"Nonclinical & clinical interface - extrapolation of nonclinical data to support phase I clinical studies","volume":"121","author":"Baldrick","year":"2021","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106240_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.yrtph.2016.08.012","article-title":"Non-clinical safety evaluation of biotherapeutics - challenges, opportunities and new insights","volume":"80","author":"Blaich","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106240_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2026.106066","article-title":"Opportunities for reducing animal use in the development of intravitreal biotherapeutics","volume":"168","author":"Booler","year":"2026","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"6","key":"10.1016\/j.yrtph.2026.106240_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/10915818221125670","article-title":"The dog as a second species for toxicology testing provides value to drug development","volume":"41","author":"Bower","year":"2022","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106240_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105329","article-title":"Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach","volume":"138","author":"Chien","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106240_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.yrtph.2007.08.001","article-title":"Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?","volume":"50","author":"Clarke","year":"2008","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106240_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.yrtph.2016.10.010","article-title":"Role of chronic toxicology studies in revealing new toxicities","volume":"82","author":"Galijatovic-Idrizbegovic","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106240_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/01926233211042256","article-title":"Opinion on maintaining in-house GLP status for toxicologic pathology in pharmaceutical and (agro)chemical development","volume":"50","author":"Gauthier","year":"2022","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2026.106240_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2026.106124","article-title":"FDA CDER analysis of non-human primate (NHP) data in monoclonal antibody (mAb) development to support the streamlining of nonclinical safety studies","volume":"170","author":"Hao","year":"2026","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106240_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.yrtph.2014.07.008","article-title":"Target organ profiles in toxicity studies supporting human dosing: an assessment of recovery and chronic dosing","volume":"70","author":"Horner","year":"2014","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106240_bib15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.yrtph.2013.02.002","article-title":"Target organ toxicities in studies conducted to support first time in man dosing: an analysis across species and therapy areas","volume":"65","author":"Horner","year":"2013","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106240_bib17","series-title":"International Conference on Harmonization: Guideline for Good Clinical Practice","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106240_bib18","series-title":"International Conference on Harmonization: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorisation for Pharmaceuticals","year":"2009"},{"key":"10.1016\/j.yrtph.2026.106240_bib19","series-title":"International Conference on Harmonization: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorisation for Pharmaceuticals: Questions & Answers (R2)","year":"2012"},{"key":"10.1016\/j.yrtph.2026.106240_bib20","series-title":"International Conference on Harmonization: Nonclinical Evaluation for Anticancer Pharmaceuticals","year":"2009"},{"key":"10.1016\/j.yrtph.2026.106240_bib21","series-title":"International Conference on Harmonization: Preclinical Safety Evaluation of biotechnology-derived Pharmaceuticals","year":"2011"},{"issue":"6","key":"10.1016\/j.yrtph.2026.106240_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00280-023-04570-3","article-title":"An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose","volume":"92","author":"Jessen","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106240_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117087","article-title":"Do longer duration nonclinical toxicology studies provide predictive clinical safety value? The IQ consortium longer duration nonclinical to clinical translational database","volume":"492","author":"Monticello","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106240_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2020.104709","article-title":"Calculating safety margins using total plasma concentration versus unbound plasma concentration - does it make a difference?","volume":"115","author":"Mukherjee","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106240_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41899-4","article-title":"CSL-Tox: an open-source analytical framework for the comparison of short-term and long-term toxicity end points and assessing the need of chronic studies in drug development","volume":"13","author":"Naga","year":"2023","journal-title":"Sci. Rep."},{"issue":"S1","key":"10.1016\/j.yrtph.2026.106240_bib26","first-page":"568","article-title":"Risk assessment of lens opacities observed in a 39-week toxicity study of SNG-30 in dogs","volume":"210","author":"Nekomoto","year":"2026","journal-title":"Tox. Sci"},{"key":"10.1016\/j.yrtph.2026.106240_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105339","article-title":"The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain","author":"Prior","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106240_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2020.104624","article-title":"Opportunities for use of one species for longer-term toxicology testing during drug development: a cross-industry evaluation","volume":"113","author":"Prior","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106240_bib30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/10915818241255885","article-title":"Exploring greater flexibility for chronic toxicity study designs to support human safety assessment while balancing 3Rs considerations","volume":"43","author":"Prior","year":"2024","journal-title":"Int. J. Toxicol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106240_bib28","first-page":"82","article-title":"Incidence of new toxicities in biologics and small molecules upon long-term dosing","volume":"40","author":"Prior","year":"2021","journal-title":"Int. J. Toxicol."},{"issue":"7","key":"10.1016\/j.yrtph.2026.106240_bib31","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jat.3954","article-title":"Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS-986260, mitigates class-based cardiovascular toxicity in dogs but not rats","volume":"40","author":"Rak","year":"2020","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106240_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105710","article-title":"Rethinking the necessity of long-term toxicity studies for biotherapeutics using weight of evidence assessment","volume":"153","author":"Rana","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106240_bib33","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.yrtph.2015.10.021","article-title":"Target organ profiles in toxicity studies supporting human dosing: does severity progress with longer duration of exposure?","volume":"73","author":"Roberts","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106240_bib34","article-title":"Recovery animals in toxicology studies: an innovation and quality consortium perspective on best practices with case study examples","author":"Salian-Mehta","year":"2024","journal-title":"Int"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106240_bib35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.yrtph.2014.07.018","article-title":"Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first in-human clinical trials","volume":"70","author":"Sewell","year":"2014","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106240_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2026.106103","article-title":"Assessment of chronic toxicity study designs and development of a weight-of-evidence-based decision-making model for biopharmaceuticals: a survey of Japanese pharmaceutical companies","volume":"169","author":"Suzuki","year":"2026","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106240_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF03262392","article-title":"Phase III trial of eprotirome","volume":"26","author":"Sweetlove","year":"2012","journal-title":"Pharm Med"},{"issue":"7","key":"10.1016\/j.yrtph.2026.106240_bib38","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026002138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026002138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:08:03Z","timestamp":1791457683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026002138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":38,"alternative-id":["S0273230026002138"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106240","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determining the value of subchronic or chronic animal toxicity testing in identifying new target organ findings","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106240"}}